Pharmaron Beijing Co., Ltd.
Pharmaron Beijing Co., Ltd. Fundamental Analysis
Pharmaron Beijing Co., Ltd. (3759.HK) shows moderate financial fundamentals with a PE ratio of 21.33, profit margin of 11.21%, and ROE of 10.70%. The company generates $20.9B in annual revenue with moderate year-over-year growth of 6.39%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 49.3/100 based on profitability, valuation, growth, and balance sheet metrics. The D grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze 3759.HK's fundamental strength across five key dimensions:
Efficiency Score
Weak3759.HK struggles to generate sufficient returns from assets.
Valuation Score
Moderate3759.HK shows balanced valuation metrics.
Growth Score
Excellent3759.HK delivers strong and consistent growth momentum.
Financial Health Score
Excellent3759.HK maintains a strong and stable balance sheet.
Profitability Score
Weak3759.HK struggles to sustain strong margins.
Key Financial Metrics
Is 3759.HK Expensive or Cheap?
P/E Ratio
3759.HK trades at 21.33 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, 3759.HK's PEG of 3.20 indicates potential overvaluation.
Price to Book
The market values Pharmaron Beijing Co., Ltd. at 2.21 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 20.19 times EBITDA. This signals the market has high growth expectations.
How Well Does 3759.HK Make Money?
Net Profit Margin
For every $100 in sales, Pharmaron Beijing Co., Ltd. keeps $11.21 as profit after all expenses.
Operating Margin
Core operations generate 13.45 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $10.70 in profit for every $100 of shareholder equity.
ROA
Pharmaron Beijing Co., Ltd. generates $5.86 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Pharmaron Beijing Co., Ltd. produces operating cash flow of $5.06B, showing steady but balanced cash generation.
Free Cash Flow
Pharmaron Beijing Co., Ltd. produces free cash flow of $1.26B, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $0.46 in free cash annually.
FCF Yield
3759.HK converts 1.63% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
21.33
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
3.20
vs 25 benchmark
P/B Ratio
Price to book value ratio
2.21
vs 25 benchmark
P/S Ratio
Price to sales ratio
3.70
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.44
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.50
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.11
vs 25 benchmark
ROA
Return on assets percentage
0.06
vs 25 benchmark
ROCE
Return on capital employed
0.09
vs 25 benchmark
How 3759.HK Stacks Against Its Sector Peers
| Metric | 3759.HK Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 21.33 | 28.31 | Better (Cheaper) |
| ROE | 10.70% | 699.00% | Weak |
| Net Margin | 11.21% | -130884.00% (disorted) | Strong |
| Debt/Equity | 0.44 | 0.34 | Weak (High Leverage) |
| Current Ratio | 1.50 | 2775.16 | Neutral |
| ROA | 5.86% | -14469.00% (disorted) | Weak |
3759.HK outperforms its industry in 2 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Pharmaron Beijing Co., Ltd.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
21.18%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
21.56%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
1.82%
Industry Style: Defensive, Growth, Innovation
Growing